Cell and Gene Therapy CDMO Solutions

We have supported the development of 10 FDA-approved cell and gene therapies and have conducted more than 900 studies in this field over the past year. Our unsurpassed end-to-end offering results in enhanced access to scientific and regulatory expertise via our multidisciplinary bench of experts to help you problem solve. Our focus is on accelerating and achieving your critical development goals from discovery to commercialization.

Consult an expert

Cell and gene therapy CDMO

Explore Our Cell and Gene Therapy CDMO Solutions


DNA SciFi Helix

High Quality Plasmid DNA: A Case for Phase Dependent Approaches to Manufacturing

Learn about the technical challenges around plasmid production and emerging regulatory guidelines.

Watch the webinar


Charles River offers end-to-end development services for cell and gene therapy research. The Charles River cell and gene therapy research scientists present various presentations sharing insights on our services offered.

Cell and Gene Therapy Development Video Series

In these videos, our experts describe critical considerations, key strategies, and the technologies that can make your program a success.

Watch Now


Microscopic, DNA

Gene Therapy, A Promising Future for Epileptic Drug Development

Cobra Biologics, now a Charles River company, and partner, CombiGene AB recently announced the successful completion of the production of plasmids for use in the treatment of drug-resistant focal epilepsy (CombiGene project CG01).

Learn more


Scientists looking through a microscope.

Tailored Preclinical Support for Your Cell & Gene Therapies

The complexity of cell and gene therapies, combined with limited regulatory precedent, makes these treatments especially challenging to develop. With the right partner, however, there’s no need to reinvent the wheel. See how we can help you design and execute a robust, efficient program that delivers accurate data to authorities.

Watch the Videos